{{Translating|||time=2018-06-20T21:40:34+00:00}}
<!--TODO:
ref貌似有重复的（4/5）-->
{{医学声明}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470615044
| IUPAC_name = 1-(2,3,4-trimethoxybenzyl)piperazine
| image = Trimetazidine.svg

<!--Clinical data-->
| tradename =Vastarel  
| Drugs.com = {{drugs.com|international|trimetazidine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = CD
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration = 口服

<!--Pharmacokinetic data-->
| bioavailability = 约5小时后完全吸收，60小时后药物浓度趋于稳定
| protein_bound = 低（16%）
| metabolism = 极少
| elimination_half-life = 7至12小时
| excretion = 主要由肾脏原状排出。肾脏受损时[[药物暴露|药物暴露]]有增长，严重受损时（CrCl <30 ml/min）平均增加3倍

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 5011-34-7
| ATC_prefix = C01
| ATC_suffix = EB15
| PubChem = 21109
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 19853
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = N9A0A0R9S8
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 203266

<!--Chemical data-->
| C=14 | H=22 | N=2 | O=3 
| molecular_weight = 266.336 g/mol
| smiles = O(c1ccc(c(OC)c1OC)CN2CCNCC2)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H22N2O3/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16/h4-5,15H,6-10H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UHWVSEOVJBQKBE-UHFFFAOYSA-N
}}
'''曲美他嗪'''（Trimetazidine）是一种治疗[[心绞痛|心绞痛]]的药物，已被冠以许多种商品名销售。<ref name=brands/>该药物是由法国{{tsl|en|Laboratoires Servier}}开发和销售的第一种[[细胞保护作用|细胞保护性]]抗缺血剂。它是一种抗缺血（抗心绞痛）代谢剂，通过抑制[[脂肪酸代谢|脂肪酸代谢]]来改善{{tsl|en|myocardial||心肌}}葡萄糖的利用，也称为脂肪酸氧化抑制剂。

== 医疗用途 ==

曲美他嗪通常被用于心绞痛的长期治疗，在一些国家（如[[法国|法国]]）还用于治疗[[耳鸣|耳鸣]]与[[头晕|头晕]]。[[欧洲药品管理局|欧洲药品管理局]]（EMA）于2012年完成了对曲美他嗪的益处和风险审查，并建议限制使用含曲美他嗪的药物，以作为一线抗心绞痛治疗不能控制或不耐受情况下的心绞痛附加治疗。<ref name = "EMA_press_release"/>

心绞痛患者的对照研究显示曲美他嗪增加了{{tsl|en|coronary flow reserve|冠脉血流储备}}，从而延缓与运动有关的缺血发作，限制了运动造成的[[血壓|血壓]]快速波动，并对[[心率|心率]]没有显著影响，显着降低了心绞痛发作的频率，并使因心绞痛而使用{{tsl|en|Glyceryl trinitrate (pharmacology)||硝酸盐}}显着减少。

在患有[[冠狀動脈疾病|冠狀動脈疾病]]的糖尿病患者中，它改善了[[心室|左心室功能]]。近期，人们发现曲美他嗪对不同病因造成的[[心脏衰竭|心脏衰竭]]都有效果。<ref name="pmid16949492">{{cite journal |vauthors=Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A | title = A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure | journal = J. Am. Coll. Cardiol. | volume = 48 | issue = 5 | pages = 992–8 |date=September 2006 | pmid = 16949492 | doi = 10.1016/j.jacc.2006.03.060  }}</ref><ref name="pmid18765391">{{cite journal |vauthors=Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, Juhani Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J | title = Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy | journal = Circulation | volume = 118 | issue = 12 | pages = 1250–8 |date=September 2008 | pmid = 18765391 | doi = 10.1161/CIRCULATIONAHA.108.778019 }}</ref>

==用作表现增强物质==
曲美他嗪被列入[[世界反兴奋剂组织|世界反兴奋剂组织]]（WADA）“激素和代谢调节剂”类别下的禁用物质清单，<ref>{{cite news |last1=Ritchie |first1=Hannah |last2=Ramsay |first2=George |title=Trimetazidine: Drug banned by WADA makes 'your heart work more efficiently' |url=https://www.cnn.com/2022/02/10/sport/trimetazidine-banned-drug-explainer-spt-intl/index.html |access-date=10 February 2022 |work=CNN |agency=CNN |publisher=CNN |date=10 February 2022 |archive-date=2022-02-10 |archive-url=https://web.archive.org/web/20220210161822/https://www.cnn.com/2022/02/10/sport/trimetazidine-banned-drug-explainer-spt-intl/index.html }}</ref>并且在任何时候都禁止在“赛内和赛外”使用它。<ref>{{cite web |title=World Anti-Doping Code International Standard Prohibited List |url=https://www.wada-ama.org/sites/default/files/2022-01/2022list_final_en_0.pdf |publisher=World Anti-Doping Agency |date=1 January 2022 |access-date=2022-02-14 |archive-date=2022-01-22 |archive-url=https://web.archive.org/web/20220122001333/https://www.wada-ama.org/sites/default/files/2022-01/2022list_final_en_0.pdf }}</ref>2014年，中国奥运会游泳冠军[[孙杨|孙杨]]对四个月前刚被禁止的曲美他嗪的检测呈阳性，因此被[[中国游泳协会|中国游泳协会]]禁赛三个月。2015年1月，WADA将曲美他嗪从“兴奋剂”重新分类并降级为“心脏代谢调节剂”。<ref>{{cite news |title=Sun Yang, el chico malo de la natación que gana todo pero al que nadie quiere |url=https://es.sports.yahoo.com/fotos/sun-yang-el-chico-malo-de-la-natacion-china-que-ha-generado-un-escandalo-en-el-mundial-113723023/photo-trimetazidine-photo-bsip-uig-via-104018948.html |publisher=yahoo.es |date=22 July 2019 |accessdate=2022-02-14 |archive-date=2022-02-09 |archive-url=https://web.archive.org/web/20220209200552/https://es.sports.yahoo.com/fotos/sun-yang-el-chico-malo-de-la-natacion-china-que-ha-generado-un-escandalo-en-el-mundial-113723023/photo-trimetazidine-photo-bsip-uig-via-104018948.html }}</ref><ref>{{Cite web|url = https://www.swimmingworldmagazine.com/news/sun-yang-doping-case/|title = The Sun Yang Doping Case: Chapter Two of an Olympic Champion|date = 2 December 2014|access-date = 2022-02-14|archive-date = 2016-09-21|archive-url = https://web.archive.org/web/20160921192411/https://www.swimmingworldmagazine.com/news/sun-yang-doping-case/}}</ref>2022年2月，原定于2月8日星期二举行的2022年奥运会花样滑冰团体项目的颁奖典礼被推迟，原因是因为[[国际奥委会|国际奥委会]]（IOC）发言人马克·亚当斯将这种情况描述为需要与[[国际滑冰联盟|国际滑冰联盟]]（ISU）“法律咨询”的情况。<ref>{{Cite web|date=9 February 2022|title=Olympic medals in team figure skating delayed by legal issue|url=https://apnews.com/article/winter-olympics-figure-skating-sports-international-olympic-committee-court-of-arbitration-for-sport-c49077705737be8a7d41a2847c2f355b|access-date=9 February 2022|website=[[The_Associated_Press|AP News]]|language=en|archive-date=2022-02-09|archive-url=https://web.archive.org/web/20220209061349/https://apnews.com/article/winter-olympics-figure-skating-sports-international-olympic-committee-court-of-arbitration-for-sport-c49077705737be8a7d41a2847c2f355b}}</ref>几家媒体在星期三报道称，该问题与俄罗斯奥委会的[[卡米拉·瓦莉娃|卡米拉·瓦莉娃]]对曲美他嗪的检测阳性有关，<ref>{{Cite news|last1=Tétrault-Farber|first1=Gabrielle|last2=Axon|first2=Iain|last3=Grohmann|first3=Karolos|date=9 February 2022|title=Figure skating-Russian media say teen star tested positive for banned drug|language=en|work=[[Reuters|Reuters]]|url=https://www.reuters.com/lifestyle/sports/figure-skating-medals-ceremony-delayed-over-legal-consultation-2022-02-09/|access-date=9 February 2022|archive-date=2022-02-09|archive-url=https://web.archive.org/web/20220209062431/https://www.reuters.com/lifestyle/sports/figure-skating-medals-ceremony-delayed-over-legal-consultation-2022-02-09/}}</ref><ref>{{cite web|url=https://www.usatoday.com/story/sports/olympics/beijing/2022/02/09/olympic-figure-skating-team-medals-delayed-russian-drug-test/6717526001/|title=Positive drug test by Russian Kamila Valieva has forced a delay of Olympic team medals ceremony|first=Christine|last=Brennan|website=[[USA_Today|USA Today]]|date=9 February 2022|access-date=2022-02-14|archive-date=2022-02-09|archive-url=https://web.archive.org/web/20220209113551/https://www.usatoday.com/story/sports/olympics/beijing/2022/02/09/olympic-figure-skating-team-medals-delayed-russian-drug-test/6717526001/}}</ref>检测于2月11日正式确认，结果待查。<ref>{{Cite web |url=https://www.bbc.com/sport/winter-olympics/60329120.amp |title=存档副本 |access-date=2022-02-14 |archive-date=2022-02-11 |archive-url=https://web.archive.org/web/20220211160413/https://www.bbc.com/sport/winter-olympics/60329120.amp }}</ref>2月9日，瓦莉娃被[[俄罗斯反兴奋剂机构|俄罗斯反兴奋剂机构]]（RUSADA）清除。IOC、WADA和ISU正对RUSADA的决定提出上诉。<ref>{{Cite web |url=https://amp.cnn.com/cnn/2022/02/10/sport/kamila-valieva-roc-drugs-test-olympics-spt-intl-hnk/index.html |title=存档副本 |access-date=2022-02-14 |archive-date=2022-02-11 |archive-url=https://web.archive.org/web/20220211042440/https://amp.cnn.com/cnn/2022/02/10/sport/kamila-valieva-roc-drugs-test-olympics-spt-intl-hnk/index.html }}</ref>

== 不良反应 ==
人们曾认为曲美他嗪是一种安全性高、耐受性好的药物<ref>Ciapponi A1, Pizarro R, Harrison J. Trimetazidine for stable angina.Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003614</ref>。 它与单胺氧化酶抑制剂相互作用。

关于曲美他嗪对死亡率，心血管事件或生活质量影响的信息很少。 使用临床重要结果比较曲美他嗪与常规抗心绞痛药物的长期随机对照试验是合理的。<ref name="pmid16235330">{{cite journal | vauthors = Ciapponi A, Pizarro R, Harrison J | title = Trimetazidine for stable angina | journal = Cochrane Database Syst Rev | volume =  | issue = 4 | pages = CD003614 | year = 2005 | pmid = 16235330 | doi = 10.1002/14651858.CD003614.pub2 | url = http://summaries.cochrane.org/CD003614/trimetazidine-for-stable-angina | access-date = 2017-02-16 | archive-date = 2012-05-15 | archive-url = https://web.archive.org/web/20120515062505/http://summaries.cochrane.org/CD003614/trimetazidine-for-stable-angina | dead-url = no }}</ref> 最近，一项国际多中心回顾性队列研究确实表明，在不同病因的心力衰竭患者中，在常规最佳治疗方案中添加曲美他嗪可以改善死亡率和发病率。<ref>Fragasso G, Rosano G, Baek Hong S, Sisakian H, Di Napoli P, Alberti L, Calori G, Kang SM, Sahakyan A, Vitale C, Marazzi G, Margonato A, Belardinelli R. Effect of partial acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol. 2013;163:320-5.</ref>

EMA建议医生不要再为有[[耳鸣|耳鸣]]、[[眩晕_(医学)|眩晕]]或视力障碍的患者开曲美他嗪。<ref name = "EMA_press_release">{{cite web | url = http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/06/WC500129070.pdf | title = European Medicines Agency recommends restricting use of trimetazidine-containing medicines | format = pdf | work = Press release | date = 2012-06-12 | publisher = European Medicines Agency | accessdate = 2017-02-16 | archive-date = 2013-04-06 | archive-url = https://web.archive.org/web/20130406224454/http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/06/WC500129070.pdf | dead-url = no }}</ref> 最近的EMA评估还显示[[帕金森症候群|帕金森症候群]](或 锥体外症候群)症状(如震颤、僵硬、运动障碍、[[张力亢进|张力亢进]]), 步态不稳, [[不宁腿综合症|不宁腿综合症]], 其他相关运动障碍的高可能性, 停药后可逆。 因此，建议医生不要给帕金森病患者，有帕金森症候群、震颤、不宁腿综合征或其他相关运动障碍的患者开药，也不要给严重[[肾功能衰竭|肾功能衰竭]]的患者开药。<ref name = "EMA_press_release"/>

== 作用机制 ==
曲美他嗪阻碍长链[[HADHB|HADHB]]生成，从而抑制[[脂肪酸|脂肪酸]]的[[β-氧化|β-氧化]]并促进葡萄糖的氧化<ref name = "Kantor_2000">{{cite journal |vauthors=Kantor PF, Lucien A, Kozak R, Lopaschuk GD | title = The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase | journal = Circ. Res. | volume = 86 | issue = 5 | pages = 580–8 |date=March 2000 | pmid = 10720420 | doi = 10.1161/01.RES.86.5.580  }}</ref>。在缺血的细胞中，要得到同样多的能量，与脂肪酸β-氧化相比，葡萄糖氧化消耗的氧气更少。因此，曲美他嗪使细胞缺血时也能获取足够的能量，并维持其代谢。这样，缺氧或缺血细胞内的ATP浓度便不会下降，这保证了离子泵与跨膜钠-钾运输的正常运作，保持着细胞的动态平衡。<ref name = "Stanley_Marzilli_2003">{{cite journal |vauthors=Stanley WC, Marzilli M | title = Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine | journal = Fundam Clin Pharmacol | volume = 17 | issue = 2 | pages = 133–45 |date=April 2003 | pmid = 12667223 | doi = 10.1046/j.1472-8206.2003.00154.x }}</ref>

==商品名==
<!--太长了，选几个放进Drugbox-->
曲美他嗪已被冠以众多品牌名分销，包括：3 Kat、Adexor、Aiyiling、Angimax、Angimet、Anginox、Angintriz、Angiozil、Angirel、Angirid、Angitrim、Angivas、Angivent、Antoris、ApoTrimet、Apstar、Atanol、Bustidin、Cardimax、Carvidon、Curime、Cyto-Protectin、Cytogard、Dilatan、Dimesar、Domisin、Energotrim、Feelnor、Idaptan、Imovexil、Intervein、Invidon、Kardin、Liomagen、Matenol、Metacard、Metacardia、Metagard、Metazydyna、Mezitan、Miozidine、Moduxin、Neotri、Novazidine、Portora、Prectazidine、Predizin、Predozone、Preductal、Predutrim、Preduxl、Protevasc、Rimecor、Setal、Sitorel、Tacirel、Tazidinol、Tazz、TevaTrim、TMZ、Triacyt、Tricardia、Triguard、Trimductal、Trimecard、Trimeductan、Trimektal、Trimeluzine、Trimepect、Trimerel、Trimet、Trimetacor、Trimetaratio、Trimetazidin、Trimetazidinã、Trimetazidine、Trimetazidinum、Trimetazigen、Trimetazydyna、Trimezar、Trimpol、Trizedon、Trizid、Trizidine、Tryme、Vascotasin、Vascotazin、Vashasan、Vasorel、Vasotrim、Vaspycar、Vastar、Vastarel、Vastazid、Vastinan、Vastinol、Vastor、Vestar、Vosfarel、Whilst、Ze Wei Er、Zidimet、Zidin、Zidmetin、Zilutra、Zimetin等。<ref name=brands>{{cite web|title=Trimetazidine – International brands|url=https://www.drugs.com/international/trimetazidine.html|publisher=Drugs.com|accessdate=7 May 2017|archive-date=2018-08-24|archive-url=https://web.archive.org/web/20180824134945/https://www.drugs.com/international/trimetazidine.html|dead-url=no}}</ref>

== 参考文献 ==
{{Reflist}}

== 拓展阅读 ==
{{refbegin}}
* {{cite journal |vauthors=Sellier P, Broustet JP | title = Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study | journal = Am J Cardiovasc Drugs | volume = 3 | issue = 5 | pages = 361–9 | year = 2003 | pmid = 14728070 | doi = 10.2165/00129784-200303050-00007 }}
* {{cite journal |vauthors=Génissel P, Chodjania Y, Demolis JL, Ragueneau I, Jaillon P | title = Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers | journal = Eur J Drug Metab Pharmacokinet | volume = 29 | issue = 1 | pages = 61–8 | year = 2004 | pmid = 15151172 | doi = 10.1007/BF03190575 }}
{{refend}}

<!--{{Piperazines}}-->

[[Category:抗心绞痛药|Category:抗心绞痛药]]
[[Category:哌嗪|Category:哌嗪]]
[[Category:芳香醚|Category:芳香醚]]
<!--[[Category:Laboratoires_Servier|Category:Laboratoires Servier]]-->
<!--[[Category:World_Anti-Doping_Agency_prohibited_substances|Category:World Anti-Doping Agency prohibited substances]]-->